1. Home
  2. DNMXU vs WGSWW Comparison

DNMXU vs WGSWW Comparison

Compare DNMXU & WGSWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DNMXU

Dynamix Corporation III Unit

N/A

Current Price

$10.08

Market Cap

0.0

Sector

N/A

ML Signal

N/A

Logo GeneDx Holdings Corp.

WGSWW

GeneDx Holdings Corp.

HOLD

Current Price

$0.02

Market Cap

0.0

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
DNMXU
WGSWW
Founded
N/A
2017
Country
United States
United States
Employees
N/A
1300
Industry
Retail: Computer Software & Peripheral Equipment
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
DNMXU
WGSWW
Price
$10.08
$0.02
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
5.5K
95.8K
Earning Date
N/A
02-18-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$305,450,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
50.79
52 Week Low
$10.05
$0.00
52 Week High
$11.00
$0.25

Technical Indicators

Market Signals
Indicator
DNMXU
WGSWW
Relative Strength Index (RSI) 45.79 51.25
Support Level $10.06 $0.01
Resistance Level $10.17 $0.02
Average True Range (ATR) 0.15 0.00
MACD -0.00 0.00
Stochastic Oscillator 1.08 72.97

Price Performance

Historical Comparison
DNMXU
WGSWW

About DNMXU Dynamix Corporation III Unit

Dynamix Corp III is a a blank check company incorporated as a Cayman Islands exempted company and incorporated for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

About WGSWW GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Share on Social Networks: